We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

59 hedge funds and large institutions have $138M invested in Orchestra BioMed in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

11% more funds holding

Funds holding: 53 → 59 (+6)

7% more capital invested

Capital invested by funds: $129M → $138M (+$8.57M)

6.04% more ownership

Funds ownership: 62.75% → 68.8% (+6%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
59
Holders Change
+6
Holders Change %
+11.32%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
10
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Saba Capital Management
New York
+$7.28M
2
SC
Sculptor Capital
New York
+$4.85M
3
RCM
Radcliffe Capital Management
Pennsylvania
+$4.02M
4
CC
Centiva Capital
New York
+$3.31M
5
WRBC
W.R. Berkley Corp
Connecticut
+$1.98M

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$7.5M
2
O
OrbiMed
New York
-$5.04M
3
KPF
K2 Principal Fund
Ontario, Canada
-$4.29M
4
M
Murchinson
Ontario, Canada
-$1.97M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
DKCM
1
Davidson Kempner Capital Management
New York
$9.66M – – –
D.E. Shaw & Co
2
D.E. Shaw & Co
New York
$8.79M +$1.07M +108,119 +14%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$7.93M – – –
BlackRock
4
BlackRock
New York
$7.88M -$21.8K -2,208 -0.3%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$7.87M -$45.5K -4,605 -0.6%
SCM
6
Saba Capital Management
New York
$7.31M +$7.28M +737,488 New
RCM
7
RA Capital Management
Massachusetts
$6.19M – – –
AC
8
Amitell Capital
Singapore
$5.95M – – –
SC
9
Sculptor Capital
New York
$4.87M +$4.85M +491,198 New
PA
10
Perceptive Advisors
New York
$4.46M – – –
RCM
11
Radcliffe Capital Management
Pennsylvania
$4.04M +$4.02M +407,274 New
WP
12
Woodline Partners
California
$4M – – –
APM
13
Avidity Partners Management
Texas
$3.96M – – –
BC
14
Boxer Capital
California
$3.96M – – –
EC
15
EcoR1 Capital
California
$3.96M – – –
ACP
16
Acuta Capital Partners
California
$3.89M – – –
CC
17
Centiva Capital
New York
$3.32M +$3.31M +334,829 New
WRBC
18
W.R. Berkley Corp
Connecticut
$3.06M +$1.98M +200,000 +184%
AAA
19
Affinity Asset Advisors
New York
$2.97M – – –
WAM
20
Weiss Asset Management
Massachusetts
$2.94M – – –
Citadel Advisors
21
Citadel Advisors
Florida
$2.59M -$16.7K -1,687 -0.6%
GL
22
Governors Lane
New York
$2.48M – – –
SCM
23
Sio Capital Management
New York
$2.48M – – –
KKRC
24
Kohlberg Kravis Roberts & Co
New York
$2.47M +$790K +79,956 +47%
BFM
25
Boothbay Fund Management
New York
$2.04M +$395K +40,019 +24%
1
2 3

OBIO Hedge Fund Activity: Q1 2022 in Review

59 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2022, worth a combined $138M — up 6.6% from $129M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new OBIO positions and 8 closed out — a net gain of 6 holders — while 10 added to existing stakes and 6 trimmed.

The largest buyer was Saba Capital Management, opening a new position worth an estimated $7.28M. The largest seller was Putnam Investments, exiting entirely with an estimated $7.5M sold.

  • 59 institutional investors held Orchestra BioMed (OBIO) as of Q1 2022, up from 53 in Q4 2021.
  • Funds reported $138M of Orchestra BioMed stock for Q1 2022, up 6.6% quarter-over-quarter.
  • 14 funds opened new Orchestra BioMed positions in Q1 2022 and 8 closed out, a net change of +6 holders.
  • The largest Orchestra BioMed buyer in Q1 2022 was Saba Capital Management, an estimated $7.28M added.
  • The largest Orchestra BioMed seller in Q1 2022 was Putnam Investments, an estimated $7.5M sold.

Based on aggregated 13F filings for Q1 2022.